InvestSMART

Vectus Biosystems Limited (ASX:VBS)

ALERT: Price-sensitive ASX Announcement for VBS
Current share price for VBS : $0.175 0.06 (52.17%)+
Announcement
Release
30 Oct 2025 6:28PM
Price at Release
$0.115
Full Release
download
Summary
Vectus Biosystems Limited presented its quarterly activities report for September 2025, highlighting its strategic actions aimed at developing and commercializing treatments for fibrosis. The company is actively working on licensing opportunities, notably signing a term sheet with XORTX Therapeutics for the VB4-P5 compound. Vectus is focusing on reducing expenditures post clinical trials while leveraging partnerships for further research and development, with a significant tax refund bolster from the Australian Taxation Office. As of the report date, the company maintained a cash balance of A$569,000 and is seeking additional funding avenues to support ongoing operations and commercialization efforts.
Key Points
  • Vectus Biosystems Limited (VBS) focuses on developing treatments for fibrosis in major organs like heart, kidney, and liver.
  • VBS's lead compound, VB0004, has shown potential in treating fibrosis and high blood pressure.
  • The company has executed a binding agreement with XORTX Therapeutics Inc. for VB4-P5, targeting renal fibrosis.
  • VBS received a significant R&D tax refund from the Australian Taxation Office.
  • VBS is working with C14 Consulting Group on commercializing its drug candidates.
  • The company is exploring potential licensing opportunities, especially in China.
  • VBS continues to manage its operations with reduced overheads and strategic partnerships.
  • Cash-on-hand as of 30 September 2025 was A$569,000, with a focus on securing additional funding.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.